Skull metastasis revealing a papillary thyroid carcinoma

Xi Li¹, Ge Zhao², Yong Zhang³, Kui Ding¹, Hui Cao¹, Dehua Yang¹, Jian Zhang¹, Zhiquan Duan¹, Shijie Xin¹

¹Department of Vascular and Thyroid Surgery, ²Department of Obstetrics, ³Department of Pathology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China

Corresponding to: Shijie Xin. Department of Vascular and Thyroid Surgery, the First Affiliated Hospital of China Medical University, Shenyang, China. Email: sjxin@mail.cmu.edu.cn.

Abstract: Although thyroid carcinoma is a relatively common form of malignancy, metastatic spread to the skull is rare. Here, we report a case of papillary thyroid carcinoma with frontal and parietal metastasis. A 61-year-old Chinese woman presented with a one year history of a growing mass on the center of the frontal and parietal bone, initially thought to be meningioma. Biopsy of the skull base mass after intracalvarium excision, indicated a tumor of thyroid origin. One month later the patient underwent a total thyroidectomy. Pathological examination confirmed a diagnosis of papillary thyroid carcinoma with frontal and parietal bone metastasis. Based on this experience, the key to successful management of the skull metastasis of thyroid carcinoma is prompt diagnosis and appropriate treatment. Skull metastasis should be considered at the outset of the clinical course of papillary thyroid cancer. To facilitate this, patients should be meticulously investigated by a multidisciplinary team to improve quality of life.

Keywords: Papillary thyroid carcinoma; frontal skull metastasis; diagnosis; treatment

Submitted Aug 10, 2013. Accepted for publication Sep 23, 2013
doi: 10.3978/j.issn.1000-9604.2013.09.05
Scan to your mobile device or view this article at: http://www.thecjcr.org/article/view/2835/3711

Introduction

Thyroid carcinomas account for approximately 1.1% of all carcinomas, and 0.2% of all carcinoma deaths (1). The incidence of thyroid carcinoma has increased in recent years. The National Cancer Institute estimates that approximately 22,500 new cases of thyroid cancer are diagnosed each year (2). Among these, differentiated thyroid carcinomas (DTC) comprising papillary and follicular thyroid carcinoma subtypes, represent more than 90% of all thyroid carcinomas.

Papillary thyroid carcinoma (PTC) is the most common type of DTC. It is classically described as having an indolent nature, as it is typically low-grade and slowly progressive. Consequently, the prognosis is usually favorable with high survival rate. The most frequently occurring metastasis affects the regional lymph nodes, especially the cervical and mediastinal nodes. The most common sites of distant metastasis are lung and bone. Bone metastases are most likely to occur in the scapula, sternum and ilium. Skull metastases are uncommon, being found in only 2.5% to 5.8% of cases of thyroid carcinoma (3).

To date, details of only ten cases of skull metastasis, including three cases of frontal skull metastasis from PTC have been published. In this article, we describe a case of frontal skull metastasis of PTC occurring 13 years after near total thyroidectomy. We also discuss and review the differential diagnosis of skull metastases arising from thyroid carcinoma together with its treatment management and prognosis.

Case report

A 61-year-old Chinese woman was admitted in our Hospital with a one year history of a growing well circumscribed mass on the center of the frontal and parietal part of the skull. Detailed medical history revealed that she had undergone a near total thyroidectomy due to thyroid adenoma 13 years ago. Physical examination showed a
1.5 cm × 1.5 cm, firm, and immobile mass of the frontal and parietal area. Neurological function and visual acuity were both normal, and physical examination was unremarkable. Laboratory studies, including tumor markers, showed no abnormalities except for increased serum thyroglobulin (138.77 IU/mL) and anti-thyroglobulin antibody levels (18.51 IU/mL). All vital signs were normal.

Coronal magnetic resonance imaging (MRI) showed an expansive, osteolytic solid tumor extending from the dura mater into the subcutis, which had begun to destroy part of the frontal and parietal bone (Figure 1A,B). Sagittal contrast-enhanced MRI images confirmed the presence of a destructive tumor on the frontal and parietal bone which was compressing the adjacent cortical sulci (Figure 1C).

The tumor originated from the epidural space, and was attached to the skull. It had begun to spread on both sides and was infiltrated by brown multilobulated, firm, vascular tumor tissue. The tumor tissue was resected at the bone level.

The histopathological report of the surgical biopsy revealed differentiated papillary thyroid carcinoma mixed with small fragments of skull bone. The nuclei of the tumor cells were enlarged, oval in shaped and overlapped each other. They had a typical ground glass appearance (Figure 2A,B). On immunohistochemical analysis, the tissue stained positively for thyroglobulin (Tg), thyroid transcription factor-1 (TTF-1), cytokeratin 19 (CK19) and Ki67 (Figure 2C,D,E,F). Thus, both morphology and immunohistochemistry supported the pathological diagnosis of skull metastasis from papillary thyroid carcinoma. Based on these findings, the tumor was definitively diagnosed as a metastasis from the papillary carcinoma of the thyroid.

Thyroid ultrasound revealed a heteroechoic lesion with increased vascularity and foci of calcification in both the left and right lobes. CT of the neck showed that the left lobe of the thyroid was enlarged with a 1.4 cm diameter, round low density lesion that had caused tracheal compression and deviation. Both investigations showed that cervical lymph nodes findings were unremarkable (Figure 3). Based on these imaging findings the patient underwent a total thyroidectomy one month later. Histopathological examination revealed a small PTC affecting part of the left side of the thyroid. Follow up CT confirmed total postoperative removal of the tumor and no complications (Figure 4).

The patient received suppressive doses of L-thyroxin for three months postoperatively. Adjuvant radiiodine treatment using 100 mCi of $^{131}$I, given orally to treat the skull base metastasis, caused no discomfort or clinical symptoms. At present, the patient is alive two years after surgery, without evidence of recurrence or metastasis during.

**Discussion**

PTC is the most common type of thyroid carcinoma, accounting for 80% of all thyroid cancers in the United States. This form of cancer is two to three-times more common among women than among male subjects. Papillary thyroid carcinoma is usually associated with slow progression, with loco regional spread to the lymph nodes in the neck. Distant metastases occur in about 10% of patients. Most studies, indicate that papillary carcinoma is the least likely subtype to show bone metastases (1.4-7%) (4).

Papillary thyroid carcinoma metastases have been reported to arise in the following areas of the skull base: sella turcica and pituitary gland (5), cavernous sinus (6), and sphenoid...
As a result of their rarity, PTC metastasis in the skull can easily be mistaken for other skull base tumors, including meningioma, schwannoma, chondrosarcoma and paraganglioma, as was the case in our subject.

Figure 3 Thyroid computed tomography (CT) shows a 1.4 cm diameter round low density shadow in the left side of the thyroid.

Figure 4 Postoperative the brain computed tomography (CT) shows that the tumor was completely resected.

sinus (7). Only three case of frontal skull metastasis from PTC have been previously published (Table 1).

As a result of their rarity, PTC metastasis in the skull can easily be mistaken for other skull base tumors, including meningioma, schwannoma, chondrosarcoma and paraganglioma, as was the case in our subject.

Figure 2 Histopathology findings. (A) The histopathological report of surgical biopsy of the frontal skull mass showed that the tumor had a thyroid follicular-like structure. A glue-like substance was formed in the follicles, partially appearing as papillary structures. The tumor was admixed with small fragments of skull bone (H&E, original magnification ×200); (B) High power view revealed enlarged, oval shaped and overlapping nuclei with a typical ground glass appearance. (H&E, original magnification ×400); (C,D,E,F) The immunohistochemistry findings were positive for Tg (C), TTF-1 (D), CK19 (E) and Ki67 (F) indicating papillary thyroid carcinoma. (original magnification ×200).
The mean period from the initial diagnosis of PTC to the detection of skull metastasis has been estimated at 23.3 years (8). However, such a long silent period between initial diagnosis is, probably atypical. Indeed, the patient described here had undergone the near total thyroidectomy due to thyroid adenoma 13 years ago.

Both clinical and radiologic evidence are important for obtaining an accurate differential diagnosis. Non-invasive diagnostic techniques such as ultrasonography (9), transillumination, CT and/or MRI-scanning are essential for detecting, localizing and assessing the extension of the lesions. An incorrect diagnosis is also likely to occur if it is based on clinical presentation and radiological findings, without a tumor biopsy.

Biopsies should be performed at the time of diagnosis and repeated postoperatively. The presence of intranuclear inclusion bodies and/or ground-glass nuclei are typical pathological findings that help to confirm the diagnosis.

Accurate diagnosis has major implications for tumor management, as different tumor types respond differently. The preferred treatment algorithm for most primary thyroid carcinomas is near-total thyroidectomy followed by postoperative radiotherapy, or $^{131}$I ablation and thyroid-stimulating hormone (TSH) suppression with levothyroxine. Thyroxine withdrawal causes prolonged TSH stimulation and may accelerate metastatic progression, with important clinical consequences, especially for patients with skull metastases. Therefore, administration of $^{131}$I therapy or radiotherapy after L-thyroxine stimulation should be considered to control residual disease and metastases (10).

Bisphosphonates are effective inhibitors of osteoclastic activity. They have been shown to reduce complications and pain, and represent an alternative approach for managing bone metastases (11). The optimal timing and duration of bisphosphonate therapy and their efficacy in preventing bone metastases is currently under investigation in clinical trials for solid tumors. Other new approaches to prevent bone metastases are also being developed, including bone resorption inhibitors, anti-angiogenic factors and gene therapy (12).

The ability of differentiated thyroid carcinomas to metastasize to the skull base cannot be accurately determined because of the lack of standardization of treatment. Primary, well-differentiated thyroid carcinomas are slow-growing and are associated with a good overall prognosis. However, this is not the case with cranial metastases. According to previous reports (Table 1) overall survival among patients undergoing definitive treatment ranged from 14 months to 3.5 years from the discovery of the metastasis. The survival of untreated patients was even shorter. Overall 5- and 10-year survival probabilities in patients with bone metastases have been estimated a 29% and 13%, respectively (13).

### Table 1 Summary of reported cases with skull metastasis from papillary thyroid carcinoma

<table>
<thead>
<tr>
<th>Case Report Age/sex</th>
<th>Metastatic Site</th>
<th>Treatment</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nagamine et al. (1985) 71/M</td>
<td>Parietal and temporal</td>
<td>Surgery, $^{131}$I</td>
<td>14 months</td>
</tr>
<tr>
<td>Lin et al. (1997) 75/F</td>
<td>Occipital (brain invasion)</td>
<td>NS</td>
<td>17 months</td>
</tr>
<tr>
<td>Coconu et al. (1998) 67/M</td>
<td>Parietal</td>
<td>Surgery</td>
<td>NS</td>
</tr>
<tr>
<td>Kusunoki et al. (2003) 70/F</td>
<td>Parietal</td>
<td>Surgery</td>
<td>NS</td>
</tr>
<tr>
<td>Miyawaki et al. (2003) 55/F</td>
<td>Parietal</td>
<td>Surgery, $^{131}$I</td>
<td>Alive at 2 years</td>
</tr>
<tr>
<td>Tetsuo et al. (2006) 74/F</td>
<td>Frontal</td>
<td>Surgery, $^{131}$I</td>
<td>Alive at 3.5 years</td>
</tr>
<tr>
<td>Feng et al. (2009) 60/F</td>
<td>Frontal</td>
<td>Surgery</td>
<td>Alive at 6 months</td>
</tr>
<tr>
<td>Mostarchid et al. (2010) 50/F</td>
<td>Temporooccipital</td>
<td>NS</td>
<td>3 months</td>
</tr>
<tr>
<td>Nigam A et al. (2012) 48/F</td>
<td>Occipitoparietal</td>
<td>Surgery, chemotherapy, radiotherapy</td>
<td>NS</td>
</tr>
<tr>
<td>Hugh SC et al. (2011) 64/F</td>
<td>Temporal</td>
<td>Surgery, radiotherapy</td>
<td>NS</td>
</tr>
<tr>
<td>Houra K et al. (2011) 76/F</td>
<td>Frontal</td>
<td>Surgery</td>
<td>Alive at 10 months</td>
</tr>
<tr>
<td>Li et al. (current case) 61/F</td>
<td>Frontal</td>
<td>Surgery, $^{131}$I</td>
<td>Alive at 2 years</td>
</tr>
</tbody>
</table>

In conclusion, metastatic thyroid tumors infringing on the skull are rare but potentially hazardous. Prompt diagnosis and appropriate treatment are essential keys to successful management. Diagnosis of a skull metastasis from thyroid carcinoma is usually based on clinical judgment, in conjunction with results of ultrasonography, transillumination, CT and/or MRI-scanning and biopsy.
findings. Although unexpected, the diagnosis of these tumors has important implications on the choice of clinical management and patient outcomes. There are currently no established treatment protocols in patients with skull metastasis from PTC. A review of previous literature indicates that effective treatment options rely on a multimodal approach of surgery followed by $^{131}$I, or external beam radiation, and chronic TSH suppression. This form of combined management can contribute to prolonged and asymptomatic survival.

Acknowledgements

Disclosure: The authors declare no conflict of interest.

References
